On November 4th, 2017, Virginia Contract Research Organization Co., Ltd. (VCRO) obtained a Phase I/IIa IND clinical go for a new chemical entity used in combination with a marketed drug for cancer therapy from the US FDA. The IND package was prepared and submitted in electronic common technical document (eCTD) format.
Congratulation! A Phase I/IIa IND of the anti-cancer combination therapy was granted by the US FDA.
On November 4th, 2017, Virginia Contract Research Organization Co., Ltd. (VCRO) obtained a Phase I/IIa IND clinical go for a new chemical entity used in combination with a marketed drug for cancer therapy from the US FDA. The IND package was prepared and submitted in electronic common technical document (eCTD) format.